Skip to main content

Table 1 Baseline participant characteristics by study group

From: The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease

Characteristic Active product Control product
  (n = 265) (n = 262)
Demographics   
 Age (years) 76.6 (8.2) 76.9 (8.2)
 Female 139 (52%) 135 (52%)
 Education after finishing primary school 6.7 (3.6) 6.4 (3.5)
 White (including Hispanic) 250 (94%) 247 (94%)
Mean time from initial AD diagnosis (months) 32.7 (25.0) 34.9 (29.6)
Duration of AD medication use (months) 28.8 (22.9) 31.5 (28.7)
Type of AD medication used   
 Acetylcholinesterase inhibitor 87 (32.8%) 92 (35.1%)
 Memantine 13 (4.9%) 19 (7.3%)
 Acetylcholinesterase inhibitor and memantine combined 164 (61.9%) 151 (57.6%)
Body mass index (kg/m2) 26.2 (4.5) 26.6 (4.6)
Mini-Mental State Examination score (out of 30) 19.5 (3.2) 19.4 (3.0)
Presence of apolipoprotein E ϵ4 allele   
 No 87 (39.2%) 84 (42.0%)
 Yes 135 (60.8%) 116 (58.0%)
 Unknown 43 62
  1. Data presented as mean (standard deviation) or number (%). AD, Alzheimer’s disease.